Skip to content
20-F

Annual Report (Foreign)

LakeShore Biopharma Co., Ltd. LSBCF LSBWF

0001213900-25-069880

← back to feed
Filed
Jul 31, 2025 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Diluted FY 2025 · Mar 31, 2025 19.16M sh
Shares Diluted restated FY 2025 · Mar 31, 2024 10.69M sh
Shares Diluted restated FY 2025 · Mar 31, 2023 6.18M sh
Shares Outstanding FY 2025 · Mar 31, 2025 20.77M sh
Capex FY 2025 · Mar 31, 2025 $1.77M
Capex FY 2025 · Mar 31, 2025 ¥12.71M
Capex FY 2025 · Mar 31, 2024 ¥44.25M
Capex FY 2025 · Mar 31, 2023 ¥52.76M
Operating Cash Flow FY 2025 · Mar 31, 2025 −$16.85M
Operating Cash Flow FY 2025 · Mar 31, 2025 −¥120.98M
Operating Cash Flow FY 2025 · Mar 31, 2024 −¥295.23M
Operating Cash Flow FY 2025 · Mar 31, 2023 −¥182.47M
Long Term Debt FY 2025 · Mar 31, 2025 $3.27M
Long Term Debt FY 2025 · Mar 31, 2025 ¥23.5M
Long Term Debt FY 2025 · Mar 31, 2024 ¥98.98M
Short Term Debt FY 2025 · Mar 31, 2025 $54.39M
Short Term Debt FY 2025 · Mar 31, 2025 ¥390.44M
Short Term Debt FY 2025 · Mar 31, 2024 ¥318.54M
Stockholders Equity FY 2025 · Mar 31, 2025 $69.62M
Stockholders Equity FY 2025 · Mar 31, 2025 ¥499.75M
Stockholders Equity FY 2025 · Mar 31, 2024 ¥585.21M
Stockholders Equity FY 2025 · Mar 31, 2023 ¥728.45M
Stockholders Equity FY 2025 · Mar 31, 2022 −¥698.97M
Current Liabilities FY 2025 · Mar 31, 2025 $114.9M
Current Liabilities FY 2025 · Mar 31, 2025 ¥824.75M
Current Liabilities FY 2025 · Mar 31, 2024 ¥802.23M
Total Liabilities FY 2025 · Mar 31, 2025 $120.91M
Total Liabilities FY 2025 · Mar 31, 2025 ¥867.91M
Total Liabilities FY 2025 · Mar 31, 2024 ¥927.82M
Current Assets FY 2025 · Mar 31, 2025 $117.33M
Current Assets FY 2025 · Mar 31, 2025 ¥842.22M
Current Assets FY 2025 · Mar 31, 2024 ¥903.17M
Total Assets FY 2025 · Mar 31, 2025 $190.53M
Total Assets FY 2025 · Mar 31, 2025 ¥1.37B
Total Assets FY 2025 · Mar 31, 2024 ¥1.51B
Eps Diluted FY 2025 · Mar 31, 2025 −$0.73
Eps Diluted FY 2025 · Mar 31, 2025 −¥5.22
Eps Diluted restated FY 2025 · Mar 31, 2024 −¥40.54
Eps Diluted restated FY 2025 · Mar 31, 2023 −¥23.55
Eps Basic FY 2025 · Mar 31, 2025 −$0.73
Eps Basic FY 2025 · Mar 31, 2025 −¥5.22
Eps Basic restated FY 2025 · Mar 31, 2024 −¥40.54
Eps Basic restated FY 2025 · Mar 31, 2023 −¥23.55
Sga Expense FY 2025 · Mar 31, 2025 $17.97M
Sga Expense FY 2025 · Mar 31, 2025 ¥128.97M
Sga Expense FY 2025 · Mar 31, 2024 ¥140.09M
Sga Expense restated FY 2025 · Mar 31, 2023 ¥72.94M
Rd Expense FY 2025 · Mar 31, 2025 $20.39M
Rd Expense FY 2025 · Mar 31, 2025 ¥146.37M
Rd Expense FY 2025 · Mar 31, 2024 ¥302.8M
Rd Expense FY 2025 · Mar 31, 2023 ¥318.7M
Net Income FY 2025 · Mar 31, 2025 −$13.93M
Net Income FY 2025 · Mar 31, 2025 −¥99.98M
Net Income FY 2025 · Mar 31, 2024 −¥433.46M
Net Income FY 2025 · Mar 31, 2023 −¥145.48M
Operating Income FY 2025 · Mar 31, 2025 −$12.02M
Operating Income FY 2025 · Mar 31, 2025 −¥86.29M
Operating Income FY 2025 · Mar 31, 2024 −¥445.83M
Operating Income FY 2025 · Mar 31, 2023 −¥139.38M
Gross Profit FY 2025 · Mar 31, 2025 $70.66M
Gross Profit FY 2025 · Mar 31, 2025 ¥507.19M
Gross Profit FY 2025 · Mar 31, 2024 ¥455.73M
Gross Profit FY 2025 · Mar 31, 2023 ¥533.84M
Cost Of Revenue FY 2025 · Mar 31, 2025 $15.01M
Cost Of Revenue FY 2025 · Mar 31, 2025 ¥107.77M
Cost Of Revenue FY 2025 · Mar 31, 2024 ¥117.69M
Cost Of Revenue FY 2025 · Mar 31, 2023 ¥153.36M
Revenue FY 2025 · Mar 31, 2025 $85.67M
Revenue FY 2025 · Mar 31, 2025 ¥614.96M
Revenue FY 2025 · Mar 31, 2024 ¥573.42M
Revenue FY 2025 · Mar 31, 2023 ¥687.2M